IPO - BriaCell Therapeutics Corp.

Form Type: 424B5

Filing Date: 2025-02-04

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004856

Filing Summary: BriaCell Therapeutics Corp. is offering 762,500 common shares at an offering price of $4.00 per share, raising a total of approximately $3.05 million. This offering follows a consolidation of its common shares on January 24, 2025. As of February 3, 2025, the last reported sale price of BriaCell's common shares was $5.04. The company is advancing its lead product candidate, Bria-IMT™, in a pivotal Phase 3 study for metastatic breast cancer. The immunotherapy has shown positive outcomes, with median overall survival of 13.4 months reported against 6.7-9.8 months in the literature. BriaCell is classified as an emerging growth company and smaller reporting company under U.S. securities regulations. The offering is being facilitated by placement agent ThinkEquity LLC and is expected to close on February 5, 2025, subject to customary conditions.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-02-03

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004684

Filing Summary: BriaCell Therapeutics Corp. is offering common shares at an offering price of $ per share through a preliminary prospectus supplement dated February 3, 2025, related to their effective registration statement under the Securities Act of 1933. The offering aims to leverage the recent share consolidation effective from January 24, 2025, allowing for the arrival of post-consolidation common shares on The Nasdaq Capital Market and TSX. The prospectus includes details regarding the sales arrangement through their exclusive placement agent, ThinkEquity LLC, detailing a 'reasonable best efforts' commitment. As of the last reported sale price on February 3, 2025, common shares were trading at $5.04, and public warrants at $0.1649. The document outlines that, pursuant to General Instruction I.B.6 of Form S-3, the aggregate market value of common shares held by non-affiliates is approximately $52.26 million based on the closing price on December 9, 2024. It also covers the risks associated with investing in these securities. The preliminary prospectus highlights BriaCell's clinical-stage biotechnology efforts, focusing on immunotherapy for cancer treatment, particularly addressing their Bria-IMT™ targeted immunotherapy for metastatic breast cancer, which is currently under a pivotal Phase 3 study. They reported promising results in clinical trials and significant advances in personalized medication efforts.

Document Link: View Document